RT Journal Article
SR Electronic
T1 Characteristics, outcome and predictors of in-hospital mortality in an elderly population from a SARS-CoV-2 outbreak in a long-term care facility
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.30.20143701
DO 10.1101/2020.06.30.20143701
A1 Trecarichi, Enrico Maria
A1 Mazzitelli, Maria
A1 Serapide, Francesca
A1 Pelle, Maria Chiara
A1 Tassone, Bruno
A1 Arrighi, Eugenio
A1 Perri, Graziella
A1 Fusco, Paolo
A1 Scaglione, Vincenzo
A1 Davoli, Chiara
A1 Lionello, Rosaria
A1 Gamba, Valentina La
A1 Marrazzo, Giuseppina
A1 Busceti, Maria Teresa
A1 Giudice, Amerigo
A1 Ricchio, Marco
A1 Cancelliere, Anna
A1 Lio, Elena
A1 Procopio, Giada
A1 Costanzo, Francesco Saverio
A1 Foti, Daniela Patrizia
A1 Matera, Giovanni
A1 Torti, Carlo
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.06.30.20143701.abstract
AB Since December 2019, coronavirus disease 2019 (COVID-19) pandemic has spread from China all over the world, many COVID-19 outbreaks have been reported in long-term care facilities (LCTF). However, data on clinical characteristics and prognostic factors in such settings are scarce. We conducted a retrospective, observational cohort study to assess clinical characteristics and baseline predictors of mortality of COVID-19 patients hospitalized after an outbreak of SARS-CoV-2 infection in a LTCF.A total of 50 patients were included. Mean age was 80 years (SD, 12 years), and 24/50 (57.1%) patients were males. A total of 42/50 (84%) patients experienced symptoms of SARS-CoV-2 infection. The overall in-hospital mortality rate was 32%. In Cox regression, significant predictors of in-hospital mortality were: hypernatremia (HR 9.12), lymphocyte count <1000 cells/µL (HR 7.45), cardiovascular diseases other than hypertension (HR 6.41), and higher levels of serum interleukin-6 (IL-6, pg/mL) (HR 1.005).Our study shows a high in-hospital mortality rate in a cohort of elderly patients with COVID-19 and hypernatremia, lymphopenia, CVD other than hypertension, and higher IL-6 serum levels were identified as independent predictors of in-hospital mortality. Further studies are necessary to better understand and confirm our findings in the setting of a LTCF outbreak of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was notified to the Ethics Committee of the Calabria Region on May 13th, 2020 and conducted in in accordance with the declaration of Helsinki. The study was carried out using retrospectively collected and anonymized data. In Italy, such studies do not require ethical approval by an Ethics Committee as determined by the Italian Drug Agency note 20 March 2008 (GU Serie Generale n. 76 31/3/2008). The need for written informed consent was waived for patients owing to the retrospective nature of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be made publicly available due to ethical restrictions imposed by Italian legislation and our Ethics Committee